The Exercise Hormones That Could Become Tomorrow’s Diabetes Drugs

What if scientists could capture some of the metabolic benefits of exercise in a medicine? Research into the connection between myokines and diabetes is bringing that possibility closer to serious scientific discussion. When skeletal muscles contract, they do more than move the body. They release signaling molecules called myokines that communicate with the liver, fat tissue, pancreas, and other organs. These signals may help regulate glucose use, inflammation, fat metabolism, and insulin sensitivity. As researchers learn more about this communication network, myokines are emerging as intriguing targets for future diabetes therapies.

Table of Contents

• What myokines reveal about diabetes and metabolic health
• How exercise-induced myokines affect metabolism
• Which myokines could inspire future diabetes drugs
• Why an exercise pill remains difficult to develop
• Conclusion
• FAQ

What Myokines Reveal About Diabetes and Metabolic Health

For many years, skeletal muscle was viewed mainly as machinery for movement. However, researchers now recognize muscle as an endocrine organ capable of sending biochemical messages throughout the body. Those messages include myokines, a diverse family of proteins and peptides released or regulated by muscle.

This discovery is particularly relevant to type 2 diabetes because skeletal muscle is a major site of insulin-mediated glucose disposal. When muscle becomes less responsive to insulin, maintaining normal blood glucose becomes more difficult. Therefore, understanding the signals produced by healthy, contracting muscle could reveal new ways to address insulin resistance.

Researchers have identified numerous myokines associated with metabolic regulation. They include interleukin-6 (IL-6), irisin, myostatin, apelin, fibroblast growth factor 21 (FGF21), meteorin-like protein, and others. Importantly, these molecules do not all perform the same function. Some influence glucose uptake, while others appear to affect inflammation, fat oxidation, mitochondrial activity, or communication between metabolic organs. A review of myokines and metabolic disorders provides a broader look at these complex signaling pathways.

This changing view of muscle also helps explain why physical activity has effects far beyond calorie expenditure. For example, resistance exercise can improve insulin sensitivity while increasing muscle strength and mass. Diabetes in Control has previously examined the effects of resistance training on insulin sensitivity, highlighting the close relationship between muscle function and metabolic health.

How Exercise-Induced Myokines Affect Metabolism

Exercise creates a rapidly changing metabolic environment. Contracting muscles require fuel, so the body must coordinate glucose availability, fatty acid use, blood flow, and energy production. Exercise-induced myokines appear to participate in that coordination.

IL-6 offers an interesting example. Although chronically elevated inflammatory IL-6 is often associated with disease, the temporary increase originating from contracting muscle during exercise has different physiological effects. Exercise-related IL-6 signaling can contribute to energy mobilization and may participate in anti-inflammatory responses. Therefore, researchers cannot simply classify a myokine as “good” or “bad.” Timing, concentration, tissue source, and metabolic context all matter.

Irisin has also received considerable attention in research on myokines and diabetes. Scientists have investigated its possible roles in energy expenditure, glucose metabolism, and changes in adipose tissue. A systematic review of exercise training in people with type 2 diabetes found that five of six included studies reported increased serum irisin following training. However, exercise protocols and responses differed considerably between studies.

Meanwhile, apelin has been linked with glucose uptake and AMPK signaling, while FGF21 is associated with glucose and lipid metabolism. Myostatin represents another interesting target because it limits muscle growth. Consequently, strategies that alter myostatin signaling could potentially affect both muscle mass and metabolic function.

The important point is that exercise does not activate one metabolic switch. Instead, it produces a coordinated biological response involving many tissues and signals. That complexity is both the attraction and the challenge of developing myokine-based treatments.

Which Myokines Could Inspire Future Diabetes Drugs?

The therapeutic idea behind myokines is appealing. Researchers could identify beneficial exercise-induced signals, determine their receptors and pathways, and then investigate treatments designed to reproduce specific metabolic effects.

Several candidates are attracting attention. Irisin continues to be investigated because of its potential links with energy metabolism. Apelin is another candidate because experimental evidence connects it with glucose uptake and metabolic signaling. FGF21 has generated substantial interest across metabolic medicine, while reducing excessive myostatin activity could potentially support healthier skeletal muscle.

Newer candidates are expanding the field further. These include meteorin-like protein, BAIBA, musclin, and other exercise-related signaling molecules. Recent research suggests that myokines may participate in glucose and lipid metabolism, mitochondrial function, inflammation, and communication between organs. However, translating these findings into treatments requires stronger evidence and a better understanding of individual pathways.

That distinction is essential. A molecule showing favorable effects in cells or animal models does not automatically become a useful diabetes medication. Researchers must establish appropriate dosing, receptor specificity, long-term safety, and meaningful benefits in humans.

Moreover, circulating myokine measurements can be difficult to interpret. Levels may vary with exercise intensity, age, body composition, fitness, timing of blood collection, and metabolic disease. As a result, standardized research methods will be important before particular myokines can become reliable biomarkers or drug targets.

Why an Exercise Pill Remains Difficult to Develop

The phrase “exercise pill” sounds compelling, but it oversimplifies what physical activity does. Exercise affects the cardiovascular system, skeletal muscle, bones, brain, blood vessels, immune system, and metabolism simultaneously. Therefore, no single myokine is likely to reproduce that entire response.

In addition, myokines often interact with one another. Researchers still do not fully understand how these signals work together or how their effects change between an acute exercise session and months of regular training. Recent reviews of myokine-based diabetes therapies therefore describe substantial therapeutic potential while emphasizing that translation remains an emerging area rather than an established diabetes treatment.

For clinicians, this means myokine research should not change current exercise recommendations. Physical activity remains an important component of type 2 diabetes management, and evidence supports several forms of structured exercise. Diabetes in Control’s guide to exercise prescription for type 2 diabetes provides a closer look at translating that evidence into practice.

Future myokine therapies could instead complement established approaches. For instance, they might eventually help patients who cannot achieve sufficient physical activity because of disability, frailty, advanced disease, or other limitations. However, such applications will require rigorous clinical trials demonstrating both safety and meaningful metabolic outcomes.

Ultimately, scientists are not simply looking for a pill that replaces a workout. Instead, they are trying to understand which biological signals produced during exercise could become useful therapeutic targets. That approach may lead to treatments that capture selected metabolic benefits while working alongside exercise, nutrition, and existing diabetes therapies.

Conclusion

Research into myokine signaling and diabetes is changing how scientists view skeletal muscle. Muscle is not simply a destination for glucose or a tool for burning calories. Instead, it acts as a communication organ that sends signals capable of influencing metabolism throughout the body.

That insight creates exciting possibilities for diabetes drug development. Yet today’s evidence does not support replacing exercise with a myokine-based medication. The more realistic goal is to understand the molecular messages generated by exercise and determine whether selected pathways can be safely targeted therapeutically.

Ultimately, tomorrow’s diabetes treatments may borrow some biological lessons from today’s workout. Until then, exercise itself remains one of the most powerful ways to activate this complex metabolic signaling network.

FAQ

What are myokines?

Myokines are signaling proteins and peptides produced or released by skeletal muscle. Many are regulated by muscle contraction and can influence other tissues throughout the body.

How are myokines connected to diabetes?

Myokines may influence insulin sensitivity, glucose uptake, inflammation, fat metabolism, and communication among metabolic organs. Researchers are studying whether changes in myokine signaling contribute to insulin resistance, obesity, and type 2 diabetes.

Could myokines become diabetes medications?

Potentially, but research remains at an early translational stage. Scientists must determine which pathways provide meaningful benefits and whether those pathways can be targeted safely and effectively in humans.

Can a myokine drug replace exercise?

Current evidence does not support that idea. Exercise produces many coordinated cardiovascular, muscular, neurological, and metabolic effects that a single drug would be unlikely to reproduce.

Which exercise-related myokines are being studied?

Frequently studied candidates include IL-6, irisin, myostatin, FGF21, apelin, meteorin-like protein, IL-15, and several other muscle-derived signaling molecules. Researchers continue to investigate how these signals affect glucose control, insulin sensitivity, inflammation, and overall metabolic health.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.